CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech which has worked faithfully but unsuccessfully to develop an one off therapy, variously referred to as Pro 140, leronlimab, along with Vyrologix.

In development of this particular therapy, CytoDyn has cast its net wide and far both geographically and in terms of potential indications.

CytoDyn’s inventories of leronlimab are building up, whether they’ll actually be being used is actually an open question.

While CYDY  happens to be dawdling, market opportunities for leronlimab as being a combination therapy in the curing of multi-drug-resistant HIV are actually closing.

I’m composing my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale of my last few shares. My first CytoDyn post, “CytoDyn: What In order to Do When It’s Too Good In order to Be True?”, set out the following prediction:

Instead I expect it to turn into a serial disappointer. CEO Pourhassan presented such a highly promotional image in the Uptick Newswire interview that I came away with a bad viewpoint of the business.

Irony of irony, the poor viewpoint of mine of the business enterprise has grown steadily, although the disappointment hasn’t been financial. Two decades ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > 6 bagger at the moment still disappoints? Therein is the story; allow me to explain.

CytoDyn acquired its much-storied treatment (which I shall mean as leronlimab) returned throughout 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor for the therapy as well as prevention of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti viral activity of HIV- infected subjects. Today’s transaction of $3.5 huge number of transfers ownership of the know-how as well as linked intellectual property from Progenics to CytoDyn, and also roughly twenty five million mg of majority drug substance…. milestone payments after commencement of a phase III clinical trial ($1.5 huge number of) along with the first brand new drug application approval ($five million), and also royalty payments of five percent of net sales after commercialization.

Since that time, CytoDyn’s helping nous, Nader Pourhassan [NP] has made this inauspicious acquisition into a springboard for CytoDyn to purchase a market place cap > $3.5 billion. It’s done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with numerous indications and numerous therapies, it’s this single treatments and a “broad pipeline of indications” since it puts it. I call such pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a likely beneficial therapy in dozens of indications.

Its opening banner on the website of its (below) shows an active organization with diverse interests albeit centered on leronlimab, several disease types, multiple publications and multiple delivering presentations.

Could it all be smoke and mirrors? That is a question I’ve been asking myself from the very start of my interest in this particular business. Judging with the multiples of a huge number of several commentary on listings accessible through Seeking Alpha’s CytoDyn Summary webpage, I’m much from alone in this particular question.

CytoDyn is a traditional battleground, or even some could say cult inventory. Its adherents are fiercely shielding of the prospects of its, quick to label any bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News